PXL01
Phase 2- Indications
- Post-surgical adhesions
Company intelligence / Profile preview
PharmaSurgics
Gothenburg, Swedenprnewswire.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Completed Phase I showing safety/tolerability of PXL01. Entered Phase II proof-of-concept study for flexor tendon repair surgery, aiming to become first pharmaceutical anti-adhesion product.
- Therapeutic areas
- OtherDermatology
- Modalities
- synthetic peptidesphysical barrier vehicle combined with pharmacological agent
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Karolinska Development AB Portfolio company relationshipSahlgrenska University Hospital Research collaboration
Beyond the preview
Go deeper on PharmaSurgics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PharmaSurgics.